BAVENCIO® (avelumab) Injection
EMD Serono is pleased to announce that on May 14, 2019 the U.S. Food and Drug Administration (FDA) approved BAVENCIO® (avelumab) Injection 20 mg/mL for a new indication, which is in combination with axitinib. BAVENCIO is co-developed and co-commercialized by EMD Serono and Pfizer Inc, and axitinib is commercialized by Pfizer Inc.
The following information is for State Society review. Please refer to the revised Full Prescribing Information for BAVENCIO.
